9 results on '"Kogner, Per"'
Search Results
2. The Swedish childhood tumor biobank: systematic collection and molecular characterization of all pediatric CNS and other solid tumors in Sweden
- Author
-
Díaz de Ståhl, Teresita, Shamikh, Alia, Mayrhofer, Markus, Juhos, Szilvester, Basmaci, Elisa, Prochazka, Gabriela, Garcia, Maxime, Somarajan, Praveen Raj, Zielinska-Chomej, Katarzyna, Illies, Christopher, Øra, Ingrid, Siesjö, Peter, Sandström, Per-Erik, Stenman, Jakob, Sabel, Magnus, Gustavsson, Bengt, Kogner, Per, Pfeifer, Susan, Ljungman, Gustaf, Sandgren, Johanna, and Nistér, Monica
- Published
- 2023
- Full Text
- View/download PDF
3. Integrative discovery of treatments for high-risk neuroblastoma.
- Author
-
Almstedt, Elin, Elgendy, Ramy, Hekmati, Neda, Rosén, Emil, Wärn, Caroline, Olsen, Thale Kristin, Dyberg, Cecilia, Doroszko, Milena, Larsson, Ida, Sundström, Anders, Arsenian Henriksson, Marie, Påhlman, Sven, Bexell, Daniel, Vanlandewijck, Michael, Kogner, Per, Jörnsten, Rebecka, Krona, Cecilia, and Nelander, Sven
- Subjects
NEUROBLASTOMA ,CHILDHOOD cancer ,DATA mining ,XENOGRAFTS ,CELL lines - Abstract
Despite advances in the molecular exploration of paediatric cancers, approximately 50% of children with high-risk neuroblastoma lack effective treatment. To identify therapeutic options for this group of high-risk patients, we combine predictive data mining with experimental evaluation in patient-derived xenograft cells. Our proposed algorithm, TargetTranslator, integrates data from tumour biobanks, pharmacological databases, and cellular networks to predict how targeted interventions affect mRNA signatures associated with high patient risk or disease processes. We find more than 80 targets to be associated with neuroblastoma risk and differentiation signatures. Selected targets are evaluated in cell lines derived from high-risk patients to demonstrate reversal of risk signatures and malignant phenotypes. Using neuroblastoma xenograft models, we establish CNR2 and MAPK8 as promising candidates for the treatment of high-risk neuroblastoma. We expect that our method, available as a public tool (targettranslator.org), will enhance and expedite the discovery of risk-associated targets for paediatric and adult cancers. We lack effective treatment for half of children with high-risk neuroblastoma. Here, the authors introduce an algorithm that can predict the effect of interventions on gene expression signatures associated with high disease processes and risk, and identify and validate promising drug targets. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. Doxorubicin-provoked increase of mitotic activity and concomitant drain of G0-pool in therapy-resistant BE(2)-C neuroblastoma.
- Author
-
Hultman, Isabell, Haeggblom, Linnea, Rognmo, Ingvild, Jansson Edqvist, Josefin, Blomberg, Evelina, Ali, Rouknuddin, Phillips, Lottie, Sandstedt, Bengt, Kogner, Per, Shirazi Fard, Shahrzad, and Ährlund-Richter, Lars
- Subjects
DOXORUBICIN ,NEUROBLASTOMA ,PLURIPOTENT stem cells ,CHILDHOOD cancer ,METASTASIS - Abstract
In this study chemotherapy response in neuroblastoma (NB) was assessed for the first time in a transplantation model comprising non-malignant human embryonic microenvironment of pluripotent stem cell teratoma (PSCT) derived from diploid bona fide hESC. Two NB cell lines with known high-risk phenotypes; the multi-resistant BE(2)-C and the drug sensitive IMR-32, were transplanted to the PSCT model and the tumour growth was exposed to single or repeated treatments with doxorubicin, and thereafter evaluated for cell death, apoptosis, and proliferation. Dose dependent cytotoxic effects were observed, this way corroborating the experimental platform for this type of analysis. Notably, analysis of doxorubicin-resilient BE(2)-C growth in the PSCT model revealed an unexpected 1,5-fold increase in Ki67-index (p<0.05), indicating that non-cycling (G0) cells entered the cell cycle following the doxorubicin exposure. Support for this notion was obtained also in vitro. A pharmacologically relevant dose (1μM) resulted in a marked accumulation of Ki67 positive BE(2)-C cells (p<0.0001), as well as a >3-fold increase in active cell cycle (i.e. cells positive staining for PH3 together with incorporation of EdU) (p<0.01). Considering the clinical challenge for treating high-risk NB, the discovery of a therapy-provoked growth-stimulating effect in the multi-resistant and p53-mutated BE(2)-C cell line, but not in the drug-sensitive p53wt IMR-32 cell line, warrants further studies concerning generality and clinical significance of this new observation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
5. Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression.
- Author
-
Westerlund, Isabelle, Yao Shi, Toskas, Konstantinos, Fell, Stuart M., Shuijie Li, Surova, Olga, Södersten, Erik, Kogner, Per, Nyman, Ulrika, Schlisio, Susanne, and Holmberg, Johan
- Subjects
NEUROBLASTOMA ,CHILDHOOD cancer ,CANCER chemotherapy ,DNA methylation ,TUMOR treatment ,PATIENTS - Abstract
Neuroblastoma is a pediatric cancer characterized by variable outcomes ranging from spontaneous regression to life-threatening progression. High-risk neuroblastoma patients receive myeloablative chemotherapy with hematopoietic stem-cell transplant followed by adjuvant retinoid differentiation treatment. However, the overall survival remains low; hence, there is an urgent need for alternative therapeutic approaches. One feature of high-risk neuroblastoma is the high level of DNA methylation of putative tumor suppressors. Combining the reversibility of DNA methylation with the differentiation-promoting activity of retinoic acid (RA) could provide an alternative strategy to treat high-risk neuroblastoma. Here we show that treatment with the DNA-demethylating drug 5-Aza-deoxycytidine (AZA) restores high-risk neuroblastoma sensitivity to RA. Combined systemic distribution of AZA and RA impedes tumor growth and prolongs survival. Genome-wide analysis of treated tumors reveals that this combined treatment rapidly induces a HIF2α-associated hypoxia-like transcriptional response followed by an increase in neuronal gene expression and a decrease in cell-cycle gene expression. A small-molecule inhibitor of HIF2α activity diminishes the tumor response to AZA+RA treatment, indicating that the increase in HIF2α levels is a key component in tumor response to AZA+RA. The link between increased HIF2α levels and inhibited tumor growth is reflected in large neuroblastoma patient datasets. Therein, high levels of HIF2α, but not HIF1α, significantly correlate with expression of neuronal differentiation genes and better prognosis but negatively correlate with key features of high-risk tumors, such as MYCN amplification. Thus, contrary to previous studies, our findings indicate an unanticipated tumor-suppressive role for HIF2α in neuroblastoma. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Protective Role of Humanin on Bortezomib-Induced Bone Growth Impairment in Anticancer Treatment.
- Author
-
Eriksson, Emma, Wickström, Malin, Perup, Lova Segerström, Johnsen, John I., Eksborg, Staffan, Kogner, Per, and Sävendahl, Lars
- Subjects
BORTEZOMIB ,CHILDHOOD cancer ,GROWTH of children ,BONE growth ,TUMORS in children ,THERAPEUTICS ,CANCER treatment - Abstract
Background Bortezomib is a proteasome inhibitor currently studied in clinical trials of childhood cancers. So far, no side effects on bone growth have been reported in treated children. However, bortezomib was recently found to induce apoptosis in growth plate chondrocytes and impair linear bone growth in treated mice. We hypothesize that [Gly
14 ] humanin (HNG), a 24-amino acid synthetic antiapoptotic peptide, can prevent bortezomib-induced bone growth impairment. Methods Mice with human neuroblastoma or medulloblastoma tumor xenografts (9-13 animals/group) received one 2-week cycle (2 injections/week) of bortezomib (0.8 mg/kg or 1.0 mg/kg), or HNG (1 µg/mouse), or the combination of HNG/bortezomib, or vehicle. Cultures of human growth plate cartilage, chondrogenic- and cancer cell lines, and immunohistochemistry for detection of proapoptotic proteins were also used. Statistical significance was evaluated by two-sided Mann-Whitney U test or by parametric or nonparametric analysis of variance. Results Bortezomib efficiently blocked the proteasome and induced pronounced impairment of linear bone growth from day 0 to day 13 (0.09 mm/day, 95% confidence interval [Cl] = 0.07 to 0.11 mm/day; vs 0.19 mm/day, 95% Cl = 0.15 to 0.23mm/day in vehicle; P< .001), an effect significantly prevented by the addition of HNG (0.15ram growth/day, 95% CI = 0.14 to 0.16mm/day; P< .001 vs bortezomib only; P= 0.03 vs vehicle). Bortezomib was highly toxic when added to cultures of human growth plate cartilage, with markedly increased apoptosis compared with control (P < .001). However, when combining with HNG, bortezomib-induced apoptosis was entirely prevented, as was Bax and PARP activation. Bortezomib delayed tumor growth, and HNG did not interfere with the anticancer effect when studied in human tumor xenografts or cell lines. Conclusions HNG prevents bortezomib-induced bone growth impairment without interfering with bortezomib's desired anti- cancer effects. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
7. Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation.
- Author
-
Cetinkaya, Cihan, Martinsson, Tommy, Sandgren, Johanna, Träger, Catarina, Kogner, Per, Dumanski, Jan, de Ståhl, Teresita Díaz, and Hedborg, Fredrik
- Subjects
NEUROBLASTOMA ,CHILDHOOD cancer ,COMBINED modality therapy ,T-test (Statistics) ,TUMORS ,DISEASE progression - Abstract
Background: Aggressive neuroblastoma remains a significant cause of childhood cancer death despite current intensive multimodal treatment protocols. The purpose of the present work was to characterize the genetic and clinical diversity of such tumors by high resolution arrayCGH profiling. Methods: Based on a 32K BAC whole-genome tiling path array and using 50-250K Affymetrix SNP array platforms for verification, DNA copy number profiles were generated for 34 consecutive high-risk or lethal outcome neuroblastomas. In addition, age and MYCN amplification (MNA) status were retrieved for 112 unfavorable neuroblastomas of the Swedish Childhood Cancer Registry, representing a 25-year neuroblastoma cohort of Sweden, here used for validation of the findings. Statistical tests used were: Fisher's exact test, Bayes moderated t-test, independent samples t-test, and correlation analysis. Results: MNA or segmental 11q loss (11q-) was found in 28/34 tumors. With two exceptions, these aberrations were mutually exclusive. Children with MNA tumors were diagnosed at significantly younger ages than those with 11q- tumors (mean: 27.4 vs. 69.5 months; p=0.008; n=14/12), and MNA tumors had significantly fewer segmental chromosomal aberrations (mean: 5.5 vs. 12.0; p<0.001). Furthermore, in the 11q- tumor group a positive correlation was seen between the number of segmental aberrations and the age at diagnosis (Pearson Correlation 0.606; p=0.037). Among nonMNA/non11q- tumors (n=6), one tumor displayed amplicons on 11q and 12q and three others bore evidence of progression from low-risk tumors due to retrospective evidence of disease six years before diagnosis, or due to tumor profiles with high proportions of numerical chromosomal aberrations. An early age at diagnosis of MNA neuroblastomas was verified by registry data, with an average of 29.2 months for 43 cases that were not included in the present study. Conclusion: MNA and segmental 11q loss define two major genetic variants of unfavorable neuroblastoma with apparent differences in their pace of tumor evolution and in genomic integrity. Other possible, but less common, routes in the development of aggressive tumors are progression of low-risk infant-type lesions, and gene amplifications other than MYCN. Knowledge on such nosological diversity of aggressive neuroblastoma might influence future strategies for therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
8. Birth characteristics and Wilms tumors in children in the Nordic countries: A register-based case-control study.
- Author
-
Schüz, Joachim, Schmidt, Lisbeth Samsø, Kogner, Per, Lähteenmäki, Päivi M., Pal, Niklas, Stokland, Tore, and Schmiegelow, Kjeld
- Subjects
NEPHROBLASTOMA ,CHILDHOOD cancer ,GESTATIONAL age ,BIRTH weight ,MULTIPLE birth - Abstract
The article presents a register-based case-control study that examines birth characteristics and Wilms tumors in children from the Nordic childhood population. The study, which was conducted from 1985 to 2006, establishes a distinct link between high birth weight and Wilms tumor in girls. Factors such as the effects of birth weight, gestational age, parental age, birth order, multiple births, and birth weight-by gestational age, is investigated. A table showing the demographic distribution of cases and of controls is presented.
- Published
- 2011
- Full Text
- View/download PDF
9. High-risk neuroblastoma tumors with 11 q-deletion display a poor prognostic, chromosome instability phenotype with later onset.
- Author
-
Carén, Helena, Kryh, Hanna, Nethander, Maria, Sjöberg, Rose-Marie, Träger, Catarina, Nilsson, Staffan, Abrahamsson, Jonas, Kogner, Per, and Martinsson, Tommy
- Subjects
CHROMOSOME abnormalities ,TUMOR diagnosis ,NEUROBLASTOMA ,CHILDHOOD cancer ,PROGNOSTIC tests - Abstract
Analysis of chromosomal aberrations is used to determine the prognosis of neuroblastomas (NBs) and to aid treatment decisions. MYCN amplification (MNA) alone is an incomplete poor prognostic factor, and chromosome llq status has recently been included in risk classification. We analyzed 165 NB tumors using high-density SNP microarrays and specifically compared the high-risk groups defined by MNA (n = 37) and llq-deletion (n = 21). Median patient age at diagnosis was 21 months for MNA tumors and 42 months for 11 q-deletion tumors, and median survival time after diagnosis was 16 months for MNA and 40 months for 11q deletion. Overall survival (at 8 years) was 35% in both groups. MNA and 1 lq deletion were almost mutually exclusive; only one case harbored both aberrations. The numbers of segmental aberrations differed significantly; the MNA group had a median of four aberrations, whereas the 11 qdeletion group had 12. The high frequency of chromosomal breaks in the 11q-deletion group is suggestive of a chromosomal instability phenotype gene located in 11q; one such gene, H2AFX, is located in 11q23.3 (within the 11q-deletion region). Furthermore, in the groups with segmental aberrations without MNA or llq deletion, the tumors with 17q gain have worse prognosis than those with segmental aberrations without 17q gain, which have a favorable outcome. This study has implications for therapy in different risk groups and stresses that genome-wide microarray analyses should be included in clinical management to fully evaluate risk, aid diagnosis, and guide treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.